New Data Shows Inflammatix Machine Learning-Based Approach of Reading Immune System is Superior to IL-6 and Other Measures in Predicting Patients at High Risk for Severe COVID-19 Burlingame, Calif., September 29, 2020  --- Inflammatix a pioneering molecular diagnostics company, announced today that the Defense Advanced Research Projects Agency (DARPA) has awarded the company up to $1.1 [...]

70+ StartX Med Innovators with Medical Breakthroughs for the Prevention, Diagnostics and Treatment of Coronavirus Mobilize Efforts to Fast-Track Public Health Needs During Pandemic

70+ StartX Med Innovators with Medical Breakthroughs for the Prevention, Diagnostics and Treatment of Coronavirus Mobilize Efforts to Fast-Track Public Health Needs During Pandemic

70+ StartX Med Innovators with Medical Breakthroughs for the Prevention, Diagnostics and Treatment of Coronavirus Mobilize Efforts to Fast-Track Public Health Needs During Pandemic

New Inflammatix study in Nature Communications outlines breakthrough in diagnosing acute infections by reading the immune system. Novel machine learning host-response-based approach forms the basis of company’s tests.

Inflammatix announced today a $32 million Series C funding. Financing will be used to advance HostDx™ tests for acute infections and sepsis to commercial launch in 2021

Inflammatix announced today an agreement with the Biomedical Advanced Research and Development Authority (BARDA), to further develop its HostDx™ tests.

Burlingame, Calif., August 6, 2019  --- Inflammatix, a molecular diagnostics company that is reimagining diagnostics, announced today that it has received the American Association for Clinical Chemistry's (AACC) Disruptive Technology Award for its rapid HostDx™ tests, which read the immune system to improve diagnosis of acute infections and sepsis. The award was based on the company's presentation [...]

Burlingame, Calif., May 16, 2019  --- Inflammatix announced today that it has been named a finalist for the American Association for Clinical Chemistry’s (AACC) Disruptive Technology Award  for its rapid HostDx™ tests, which read the immune system to improve diagnosis of acute infections and sepsis. Inflammatix is one of three finalists that will present its technology at the 71st [...]

Burlingame, Calif., October 4, 2018  --- Inflammatix today announced that it will present findings from two studies demonstrating the ability of its HostDx™ Fever test to distinguish bacterial from viral infections on multiple rapid laboratory platforms that can deliver results in under 30 minutes. The new data will be presented at the Infectious Diseases Society of [...]